Brink M, Senekal M, Dicks L M T
Department of Physiological Sciences, Stellenbosch University, W Cape.
S Afr Med J. 2005 Feb;95(2):114-9.
Probiotic and prebiotic products manufactured in South Africa were identified and health and content claims stated on the labels were evaluated according to available scientific evidence, the proposed South African regulations in the Foodstuffs, Cosmetics and Disinfectants Act (Act No. 54 of 1972, www.doh.gov.za), and microbial assessment.
The range of products identified included probiotic- and/or prebiotic-containing supplements (capsules), food items fortified with probiotics and/or prebiotics, and fermented food containing probiotics, e.g. dairy products. Most of the health-related claims on the labels of the identified products do not comply with proposed South African regulations. However, results also indicate that the proposed South African regulations should be reconsidered to include an additional 5 claims, for which scientifically sound evidence is available. The claims regarding probiotic strains, viable cell numbers, prebiotic type and concentration stated on the labels of the products are mostly in line with the proposed South African regulations. The actual viable cell content of 3 out of 5 probiotic supplements readily available on the South African market did not comply with the content claim stated on the label. However, this problem did not seem to affect the inhibitory activity of the probiotic strains against indicator strains isolated from faeces of patients diagnosed with AIDS. To validate this finding in vivo assessments should be implemented before considering the need to include a wider range of prescribed viable cell numbers in the proposed South African regulations.
The proposed South African regulations regarding probiotic- and prebiotic-containing products should be revised based on the results of this research, and the manufacturers of these products should be held responsible for providing the consumer with scientifically sound and legally correct information.
识别在南非生产的益生菌和益生元产品，并根据现有科学证据、《食品、化妆品和消毒剂法案》（1972年第54号法案，www.doh.gov.za）中拟议的南非法规以及微生物评估，对标签上声明的健康和成分宣称进行评估。
识别出的产品范围包括含益生菌和/或益生元的补充剂（胶囊）、添加了益生菌和/或益生元的食品以及含有益生菌的发酵食品，如乳制品。所识别产品标签上的大多数与健康相关的宣称不符合拟议的南非法规。然而，结果也表明，拟议的南非法规应重新考虑纳入另外5项有充分科学证据支持的宣称。产品标签上关于益生菌菌株、活细胞数量、益生元类型和浓度的宣称大多符合拟议的南非法规。南非市场上随时可得的5种益生菌补充剂中有3种的实际活细胞含量不符合标签上声明的含量宣称。然而，这一问题似乎并未影响益生菌菌株对从艾滋病确诊患者粪便中分离出的指示菌株的抑制活性。为了在体内评估中验证这一发现，在考虑是否需要在拟议的南非法规中纳入更广泛的规定活细胞数量范围之前，应进行体内评估。
应根据本研究结果修订拟议的南非关于含益生菌和益生元产品的法规，并且这些产品的制造商应负责向消费者提供科学合理且合法正确的信息。
Zotero 插件